Prompt Initiation of MOUD After Opioid Overdose in U.S. Medicaid Patients

Overview

This study analyzed national Medicaid data from 2014–2019 to evaluate initiation of medication for opioid use disorder (MOUD) following acute care visits for opioid overdose. Findings highlight low rates of new MOUD initiation post-overdose despite high risk of repeat overdose and death, with disparities influenced by patient and community characteristics.

Background

Opioid overdoses remain a major public health crisis in the U.S., with over 105,000 drug poisoning deaths in 2023, most involving opioids. Emergency departments and inpatient settings are critical intervention points for connecting survivors to effective MOUD treatments such as buprenorphine, methadone, and naltrexone. Although MOUD reduces risk of subsequent overdose and death, uptake after overdose remains low, especially for new treatment initiation. Medicaid is the largest payer for addiction treatment, yet data on post-overdose MOUD initiation in this population have been limited.

Data Highlights

The study utilized 2014–2019 national Medicaid claims data covering all 50 states and DC, focusing on opioid overdose events treated in emergency or inpatient settings among adults aged 18–64. Overdoses were identified using ICD-9 and ICD-10 codes, excluding intentional self-poisoning, with a 180-day baseline period free of overdose codes to identify incident events. MOUD receipt was tracked for 180 days post-discharge, categorizing baseline MOUD exposure by proportion of days covered. Patient demographics, clinical comorbidities, overdose severity, and community-level factors were also analyzed to assess associations with MOUD initiation.

Key Findings

• Post-overdose MOUD initiation rates in the Medicaid population were low, with many patients not starting new treatment despite elevated risk.
• Most individuals receiving MOUD after overdose had prior treatment exposure, indicating limited new treatment uptake.
• Patient factors such as age, race/ethnicity, Medicaid eligibility basis, and behavioral health comorbidities influenced likelihood of MOUD initiation.
• Community characteristics including geographic region, urbanicity, and socioeconomic disadvantage were associated with variations in MOUD receipt.
• Overdose severity indicators, such as inpatient hospitalization and mechanical ventilation, were considered but did not fully explain low treatment initiation rates.

Clinical Implications

Acute care encounters for opioid overdose represent critical opportunities to initiate MOUD, yet current treatment initiation rates remain suboptimal in the Medicaid population. Clinicians should prioritize linkage to MOUD, especially for patients without prior treatment history, and consider sociodemographic and community factors that may impact access. Enhancing post-overdose care coordination and addressing barriers in disadvantaged communities could improve treatment engagement and reduce repeat overdoses.

Conclusion

Despite strong evidence supporting MOUD efficacy, initiation following opioid overdose in Medicaid patients is insufficient, particularly for new treatment starts. Targeted interventions addressing patient and community disparities are needed to improve MOUD uptake and reduce opioid-related morbidity and mortality.

References

1. CDC/NCHS 2023 -- Drug Overdose Deaths in the United States
2. CMS T-MSIS Analytic Files 2014–2019 -- Medicaid Claims Data
3. National Academies of Sciences 2019 -- Medications for Opioid Use Disorder Save Lives